Propanc Biopharma Reports Preclinical Data on PRP Formulation

The company said preclinical data suggest its PRP formulation may make chemotherapy-resistant pancreatic cancer cells more vulnerable to subsequent chemotherapy. A Phase 1b first-in-human study is expected in Q1 2027.